Taking Stock
Shire's Ornskov on $1 Billion Potential for Dry-Eye Drug(Audio)
- Autor: Vários
- Narrador: Vários
- Editor: Podcast
- Duración: 0:08:45
- Mas informaciones
Informações:
Sinopsis
(Bloomberg) -- Taking Stock with Kathleen Hays and Pimm Fox. GUEST: Shire CEO Flemming Ornskov on the outlook for the company after getting FDA approval for Xiidra drops to treat dry-eye disease.
